David Bursill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
David Bursill has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Abhishek Abhishek
Department of Academic Rheumatology, University of Nottingham, Nottingham, UK
1 shared publicationAlexander K So
Department of Musculoskeletal Medicine, Service de RMR, Lausanne, Switzerland
1 shared publication- Ana Beatriz Vargas-Santos
Universidade do Estado do Rio de Janeiro, Brazil
1 shared publication - Angelo Lino Gaffo
The University of Alabama at Birmingham and the Birmingham VA Medical Center Birmingham Alabama
1 shared publication - Anita Lee
The University of Adelaide and Rheumatology Department, Royal Adelaide Hospital, Adelaide, Australia
1 shared publication Ann Rosenthal
Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
1 shared publication
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 80
Co-occurrence of rheumatoid arthritis and calcium pyrophosphate deposition disease: A systematic literature review
- 29 July 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 80
Open AccessCo-occurrence of rheumatoid arthritis and calcium pyrophosphate deposition disease: A systematic literature review
- 9 September 2019
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 78 (11) , 1592-1600
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout
Objective There is a lack of standardisation in the terminology used to describe gout. The aim of this project was to develop a consensus statement describing the recommended nomenclature for disease states of gout. Methods A content analysis of gout-related articles from rheumatology and general internal medicine journals published over a 5-year period identified potential disease states and the labels commonly assigned to them. Based on these findings, experts in gout were invited to participate in a Delphi exercise and face-to-face consensus meeting to reach agreement on disease state labels and definitions. Results The content analysis identified 13 unique disease states and a total of 63 unique labels. The Delphi exercise (n=76 respondents) and face-to-face meeting (n=35 attendees) established consensus agreement for eight disease state labels and definitions. The agreed labels were as follows: ‘asymptomatic hyperuricaemia’, ‘asymptomatic monosodium urate crystal deposition’, ‘asymptomatic hyperuricaemia with monosodium urate crystal deposition’, ‘gout’, ‘tophaceous gout’, ‘erosive gout’, ‘first gout flare’ and ‘recurrent gout flares’. There was consensus agreement that the label ‘gout’ should be restricted to current or prior clinically evident disease caused by monosodium urate crystal deposition (gout flare, chronic gouty arthritis or subcutaneous tophus). Conclusion Consensus agreement has been established for the labels and definitions of eight gout disease states, including ‘gout’ itself. The Gout, Hyperuricaemia and Crystal-Associated Disease Network recommends the use of these labels when describing disease states of gout in research and clinical practice.
- 9 September 2019
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 78 (11) , 1592-1600
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout
Objective There is a lack of standardisation in the terminology used to describe gout. The aim of this project was to develop a consensus statement describing the recommended nomenclature for disease states of gout. Methods A content analysis of gout-related articles from rheumatology and general internal medicine journals published over a 5-year period identified potential disease states and the labels commonly assigned to them. Based on these findings, experts in gout were invited to participate in a Delphi exercise and face-to-face consensus meeting to reach agreement on disease state labels and definitions. Results The content analysis identified 13 unique disease states and a total of 63 unique labels. The Delphi exercise (n=76 respondents) and face-to-face meeting (n=35 attendees) established consensus agreement for eight disease state labels and definitions. The agreed labels were as follows: ‘asymptomatic hyperuricaemia’, ‘asymptomatic monosodium urate crystal deposition’, ‘asymptomatic hyperuricaemia with monosodium urate crystal deposition’, ‘gout’, ‘tophaceous gout’, ‘erosive gout’, ‘first gout flare’ and ‘recurrent gout flares’. There was consensus agreement that the label ‘gout’ should be restricted to current or prior clinically evident disease caused by monosodium urate crystal deposition (gout flare, chronic gouty arthritis or subcutaneous tophus). Conclusion Consensus agreement has been established for the labels and definitions of eight gout disease states, including ‘gout’ itself. The Gout, Hyperuricaemia and Crystal-Associated Disease Network recommends the use of these labels when describing disease states of gout in research and clinical practice.